Minimal Residual Disease Finding the Right Test for the New Definition of Remission
Measurement of Residual Disease for improved oncology trial outcomes
Today, measurement of minimal residual disease (MRD) is one of the most reliable predictors of treatment outcomes for leukemia and lymphoma, and myeloma.
There are multiple measurement approaches for MRD testing and key criteria to consider when selecting the right tool for MRD detection.
Download this insight brief to discover what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.
Mark Edinger, Director, Scientific Advisor, Flow Cytometry
Victor Weigman, Director, Translational Genomics
Patrick Hurban, Scientific Advisor; Senior Director and Global Head, Translational Genomics
Alan Wookey, Global Science Lead, Companion Diagnostics & Scientific Advisor, Oncology
Franklin Sederat, Director of Homatopathology
Patrice Hugo, Chief Scientific Officer
Complete the form below to access this insight brief